Recent study reveals how ovarian cancer starts in high-risk women
Stem cell scientists have revealed the origins of ovarian cancer by modeling the tissues of the fallopian tubes, allowing them to characterize how a genetic mutation puts women at high risk of developing this cancer. The tissues created, known as
FDA Approves ‘Glow Tumors’ Drug to Help Surgeons Identify Ovarian Cancer Cells.
Cytalux (pafolacianince), a drug that binds to ovarian cancer tissue and glows when exposed to fluorescent light, has been approved by the US Food and Drug Administration (FDA) to help surgeons detect ovarian tumors during surgical procedures in patients.